A Phase 1 interventional study of Sapanisertib in Advanced Solid Tumors, sponsored by Calithera Biosciences, Inc. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-23.
Sponsored by Calithera Biosciences, Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to characterize the effect of a single dose of 40 mg sapanisertib (MLN0128) on the electrocardiographic QT/QTc interval in participants with advanced solid tumors.
The drug being tested in this study is called sapanisertib (MLN0128). Sapanisertib is being tested to determine the effect of a single 40 mg dose on the electrocardiographic measure of the time between the start of the Q wave and the end of the T wave in the electrical cycle of the heart (QT)/rate corrected QT (QTc) interval in patients with advanced solid tumors. This study will look at electrocardiogram (ECG) results before and after a single dose of sapanisertib.
The study will enroll approximately 30 patients. All participants will receive a single 40 mg dose of sapanisertib capsules on Day 1. Participants may continue to receive sapanisertib for up to 1 year at a dose of up to 30 mg once weekly if a clinical benefit is being derived.
This multi-centre trial will be conducted in the United States. The overall time to participate in this study is up to 14 months. Participants will make 6 visits to the clinic and end of study visit 30 to 40 days after last dose of study drug for a follow-up assessment. Participants that continue treatment with sapanisertib will continue to make additional visits to the clinic once or twice every 4 weeks and the end of study visit 30 to 40 days after last dose of study drug for a follow-up assessment.
Calithera Biosciences, Inc is the lead sponsor of 29 studies on the registry; none are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 10 (59%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sapanisertib starting dose of 40 mg, capsules, orally, once, on Day 1, Cycle 1 (28 days cycle) followed by sapanisertib 30 mg, capsules, orally, once weekly (QW) starting on Cycle 1, Day 8 based on safety and tolerability and as per investigator's discretion up to disease progression, unacceptable sapanisertib-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurred first).
Drug: Sapanisertib
Sapanisertib capsules.
Also known as: MLN0128, INK128, TAK-228
Mean Change From Time-Matched Baseline in QTcI, Individual Baseline Corrected Rate-Corrected QT Interval
The mean changes of QTcI from time-matched baseline was measured by electrocardiogram (ECG) to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcI interval.
Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Number of Participants With Atleast One Adverse Event (AE) and Serious Adverse Event (SAE)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.
Time frame: From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months)
Number of Participants With Potentially Clinically Significant Abnormal Laboratory Values Reported as AE
The laboratory parameters included clinical chemistry, hematology, and urinalysis. Any abnormal change in the laboratory values were assessed by Investigator and reported as AE. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.
Time frame: From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months)
Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Reported as AE
Vital sign measurements included blood pressure (diastolic and systolic), heart rate, and temperature. Any abnormal change in the vital sign values were assessed by Investigator and reported as AE. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.
Time frame: From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months)
Mean Change From Time-Matched Baseline in QTc With Rate-Corrected QT Interval With Bazett Correction (QTcB)
The mean changes of QTcB from time-matched baseline was measured by ECG to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcB interval.
Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Mean Change From Time-Matched Baseline in QTc With Rate-Corrected QT Interval Fridericia Correction (QTcF)
The mean changes of QTcF from time-matched baseline was measured by ECG to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcF interval.
Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Change From Time-Matched Baseline in QRS Interval
QRS interval is defined as the time between the start of the Q wave and end of the S wave on ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QRS interval.
Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Change From Time-Matched Baseline in PR Interval
PR interval is defined as the time between the start of the P wave and the beginning of the QRS complex on ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of PR interval.
Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Change From Time-Matched Baseline in Heart Rate
Heart rate was assessed using the ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measure mixed effects linear model. A negative change from baseline indicates decrease in heart rate.
Time frame: Baseline; Cycle 1 (28 days cycle): 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 48 hours postdose
Cmax: Maximum Observed Plasma Concentration for Sapanisertib
Time frame: Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose
Tmax: Time to Reach Cmax for Sapanisertib
Time frame: Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose
AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration for Sapanisertib
Time frame: Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose
AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib
Time frame: Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose
T1/2: Terminal Elimination Half-life for Sapanisertib
Time frame: Cycle 1 (28 days cycle), Day 1, predose and at multiple timepoints (Up to 48 hours) postdose
Participants took part in the study at 5 investigative sites in the United States from 15 Sep 2014 to 28 Feb 2019.
| Milestone | Sapanisertib |
|---|---|
| Started | 44 |
| Completed | 0 |
| Not completed | 44 |
| Withdrew: Progressive disease | 28 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Adverse event | 3 |
| Withdrew: Reason not specified | 4 |
The mean changes of QTcI from time-matched baseline was measured by electrocardiogram (ECG) to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcI interval.
| msec | Sapanisertib |
|---|---|
| Change from Baseline at 0.25 Hours Postdose | -1.3 ± 9.5 |
| Change from Baseline at 0.5 Hours Postdose | -7.7 ± 9.8 |
| Change from Baseline at 1 Hour Postdose | -1.1 ± 11.5 |
| Change from Baseline at 1.5 Hours Postdose | -2.0 ± 12.5 |
| Change from Baseline at 2 Hours Postdose | -4.2 ± 11.2 |
| Change from Baseline at 2.5 Hours Postdose | -6.9 ± 10.6 |
| Change from Baseline at 3 Hours Postdose | -8.5 ± 11.2 |
| Change from Baseline at 4 Hours Postdose | -6.6 ± 9.3 |
| Change from Baseline at 6 Hours Postdose | -8.8 ± 15.6 |
| Change from Baseline at 8 Hours Postdose | -1.3 ± 14.1 |
| Change from Baseline at 10 Hours Postdose | -5.6 ± 17.5 |
| Change from Baseline at 24 Hours Postdose | 7.1 ± 25.4 |
| Change from Baseline at 48 Hours Postdose | 3.1 ± 17.8 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.
| Participants | Sapanisertib |
|---|---|
| AE | 43 |
| SAE | 18 |
The laboratory parameters included clinical chemistry, hematology, and urinalysis. Any abnormal change in the laboratory values were assessed by Investigator and reported as AE. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.
| Participants | Sapanisertib |
|---|---|
| Blood Creatinine Increased | 2 |
| Blood Triglycerides Increased | 2 |
| Hyperglycemia | 8 |
| Hypertriglyceridemia | 1 |
| Hypomagnesemia | 1 |
| Hypophosphatemia | 2 |
| Vitamin D Deficiency | 2 |
| Anemia | 3 |
| Thrombocytopenia | 1 |
Vital sign measurements included blood pressure (diastolic and systolic), heart rate, and temperature. Any abnormal change in the vital sign values were assessed by Investigator and reported as AE. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.
| Participants | Sapanisertib |
|---|---|
| Hypotension | 1 |
| Postoperative Fever | 1 |
| Pyrexia | 4 |
The mean changes of QTcB from time-matched baseline was measured by ECG to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcB interval.
| msec | Sapanisertib |
|---|---|
| Change from Baseline at 0.25 Hours Postdose | -1.9 ± 9.7 |
| Change from Baseline at 0.5 Hours Postdose | -9.8 ± 12.1 |
| Change from Baseline at 1 Hour Postdose | -2.0 ± 12.4 |
| Change from Baseline at 1.5 Hours Postdose | -3.1 ± 13.5 |
| Change from Baseline at 2 Hours Postdose | -5.1 ± 11.4 |
| Change from Baseline at 2.5 Hours Postdose | -7.5 ± 10.6 |
| Change from Baseline at 3 Hours Postdose | -8.3 ± 14.6 |
| Change from Baseline at 4 Hours Postdose | -8.5 ± 8.7 |
| Change from Baseline at 6 Hours Postdose | -5.9 ± 12.2 |
| Change from Baseline at 8 Hours Postdosen | 1.9 ± 13.7 |
| Change from Baseline at 10 Hours Postdose | -4.4 ± 15.3 |
| Change from Baseline at 24 Hours Postdose | 11.9 ± 17.0 |
| Change from Baseline at 48 Hours Postdose | 7.6 ± 14.9 |
The mean changes of QTcF from time-matched baseline was measured by ECG to evaluate the potential effect of drug on QTc interval duration. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QTcF interval.
| msec | Sapanisertib |
|---|---|
| Change from Baseline at 0.25 Hours Postdose | -1.3 ± 8.5 |
| Change from Baseline at 0.5 Hours Postdose | -5.0 ± 10.6 |
| Change from Baseline at 1 Hour Postdose | 2.1 ± 12.0 |
| Change from Baseline at 1.5 Hours Postdose | 0.6 ± 12.7 |
| Change from Baseline at 2 Hours Postdose | -3.3 ± 12.2 |
| Change from Baseline at 2.5 Hours Postdose | -7.0 ± 11.1 |
| Change from Baseline at 3 Hours Postdose | -7.4 ± 13.2 |
| Change from Baseline at 4 Hours Postdose | -7.7 ± 10.3 |
| Change from Baseline at 6 Hours Postdose | -10.1 ± 13.0 |
| Change from Baseline at 8 Hours Postdose | -4.0 ± 15.1 |
| Change from Baseline at 10 Hours Postdose | -11.9 ± 16.1 |
| Change from Baseline at 24 Hours Postdose | 0.8 ± 16.0 |
| Change from Baseline at 48 Hours Postdose | 2.5 ± 13.2 |
QRS interval is defined as the time between the start of the Q wave and end of the S wave on ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of QRS interval.
| msec | Sapanisertib |
|---|---|
| Change from Baseline at 0.25 Hours Postdose | -0.7 ± 3.3 |
| Change from Baseline at 0.5 Hours Postdose | -1.4 ± 3.3 |
| Change from Baseline at 1 Hour Postdose | -2.8 ± 2.9 |
| Change from Baseline at 1.5 Hours Postdose | -1.8 ± 4.1 |
| Change from Baseline at 2 Hours Postdose | -1.4 ± 4.0 |
| Change from Baseline at 2.5 Hours Postdose | -2.3 ± 4.7 |
| Change from Baseline at 3 Hours Postdose | -2.4 ± 3.2 |
| Change from Baseline at 4 Hours Postdose | -2.9 ± 3.2 |
| Change from Baseline at 6 Hours Postdose | -1.3 ± 3.0 |
| Change from Baseline at 8 Hours Postdosen | -0.8 ± 4.1 |
| Change from Baseline at 10 Hours Postdose | -4.0 ± 6.5 |
| Change from Baseline at 24 Hours Postdose | -1.4 ± 4.0 |
| Change from Baseline at 48 Hours Postdose | 0.2 ± 5.3 |
PR interval is defined as the time between the start of the P wave and the beginning of the QRS complex on ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measures mixed effects linear model. A negative change from baseline indicates shortening and a positive change from baseline indicates prolongation of PR interval.
| msec | Sapanisertib |
|---|---|
| Change from Baseline at 0.25 Hours Postdose | -1.8 ± 13.9 |
| Change from Baseline at 0.5 Hours Postdose | -0.8 ± 13.6 |
| Change from Baseline at 1 Hour Postdose | 0.7 ± 11.5 |
| Change from Baseline at 1.5 Hours Postdose | -0.7 ± 11.4 |
| Change from Baseline at 2 Hours Postdose | -1.7 ± 9.3 |
| Change from Baseline at 2.5 Hours Postdose | 0.1 ± 11.7 |
| Change from Baseline at 3 Hours Postdose | -2.7 ± 10.8 |
| Change from Baseline at 4 Hours Postdose | -1.9 ± 13.3 |
| Change from Baseline at 6 Hours Postdose | -8.9 ± 13.2 |
| Change from Baseline at 8 Hours Postdosen | -7.3 ± 11.4 |
| Change from Baseline at 10 Hours Postdose | -12.3 ± 11.5 |
| Change from Baseline at 24 Hours Postdose | -6.8 ± 15.7 |
| Change from Baseline at 48 Hours Postdose | -2.9 ± 20.7 |
Heart rate was assessed using the ECG. Holter monitors were used to collect triplicate ECG measurements and were based on a repeated measure mixed effects linear model. A negative change from baseline indicates decrease in heart rate.
| beats per minute (bpm) | Sapanisertib |
|---|---|
| Change from Baseline at 0.25 Hours Postdose | -0.9 ± 5.7 |
| Change from Baseline at 0.5 Hours Postdose | -4.7 ± 5.9 |
| Change from Baseline at 1 Hour Postdose | -4.2 ± 6.6 |
| Change from Baseline at 1.5 Hours Postdose | -3.7 ± 6.0 |
| Change from Baseline at 2 Hours Postdose | -1.0 ± 8.2 |
| Change from Baseline at 2.5 Hours Postdose | -0.3 ± 4.8 |
| Change from Baseline at 3 Hours Postdose | -0.3 ± 7.2 |
| Change from Baseline at 4 Hours Postdose | -0.4 ± 10.1 |
| Change from Baseline at 6 Hours Postdose | 4.8 ± 6.3 |
| Change from Baseline at 8 Hours Postdose | 7.0 ± 9.7 |
| Change from Baseline at 10 Hours Postdose | 7.9 ± 9.2 |
| Change from Baseline at 24 Hours Postdose | 12.4 ± 11.8 |
| Change from Baseline at 48 Hours Postdose | 5.0 ± 9.8 |
| ng/mL | Sapanisertib |
|---|---|
| Cmax: Maximum Observed Plasma Concentration for Sapanisertib | 337.1 ± 178.27 |
| hours | Sapanisertib |
|---|---|
| Tmax: Time to Reach Cmax for Sapanisertib | 1.5167 (0.500 to 24.000) |
| h*ng/mL | Sapanisertib |
|---|---|
| AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration for Sapanisertib | 2875.7406 ± 2110.90918 |
| h*ng/mL | Sapanisertib |
|---|---|
| AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib | 2992.5394 ± 2405.41705 |
| hours | Sapanisertib |
|---|---|
| T1/2: Terminal Elimination Half-life for Sapanisertib | 9.0682 (4.477 to 16.867) |
Collected over From first dose of study drug through 30 days after the last dose of study drug (Up to 13 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sapanisertib | 2/44 (4.5%) | 18/44 (40.9%) | 43/44 (97.7%) |
| Event | Sapanisertib |
|---|---|
| Flank PainMusculoskeletal and connective tissue disorders | 2/44 |
| Small Intestinal ObstructionGastrointestinal disorders | 1/44 |
| Small Intestinal PerforationGastrointestinal disorders | 1/44 |
| StomatitisGastrointestinal disorders | 1/44 |
| FatigueGeneral disorders | 1/44 |
| Non-Cardiac Chest PainGeneral disorders | 1/44 |
| Bile Duct ObstructionHepatobiliary disorders | 1/44 |
| HypersensitivityImmune system disorders | 1/44 |
| AppendicitisInfections and infestations | 1/44 |
| PyelonephritisInfections and infestations | 1/44 |
| Event | Sapanisertib |
|---|---|
| NauseaGastrointestinal disorders | 35/44 |
| FatigueGeneral disorders | 28/44 |
| VomitingGastrointestinal disorders | 25/44 |
| Decreased AppetiteMetabolism and nutrition disorders | 22/44 |
| DiarrhoeaGastrointestinal disorders | 15/44 |
| Weight DecreasedInvestigations | 14/44 |
| Urinary Tract InfectionInfections and infestations | 13/44 |
| StomatitisGastrointestinal disorders | 10/44 |
| ConstipationGastrointestinal disorders | 9/44 |
| Back PainMusculoskeletal and connective tissue disorders | 9/44 |
Safety population included all participants who received at least 1 dose of Sapanisertib.
| Age, Continuous(years) | Sapanisertib |
|---|---|
| Mean | 58.6 ± 12.24 |
| Sex: Female, Male(Participants) | Sapanisertib |
|---|---|
| Female | 28 |
| Male | 16 |
| Ethnicity (NIH/OMB)(Participants) | Sapanisertib |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 29 |
| Unknown or Not Reported | 8 |
| Race (NIH/OMB)(Participants) | Sapanisertib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 30 |
| More than one race | 0 |
| Unknown or Not Reported | 5 |
| Height(cm) | Sapanisertib |
|---|---|
| Mean | 166.8 ± 8.61 |
| Weight(kg) | Sapanisertib |
|---|---|
| Mean | 74.9 ± 16.08 |
| Body Mass Index (BMI)(kg/m^2) | Sapanisertib |
|---|---|
| Mean | 27.141 ± 5.8591 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Sep 2014 to primary completion in Jun 2016, 20 months.
Results were first posted in Mar 2020, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sapanisertib